Bisantrene in relapsed and refractory acute myelogenous leukemia

Antonio Spadea, Maria Concetta Petti, Maria Antonietta Aloespiriti, Giuseppe Avvisati, Cinzia De Gregoris, Paola Fazi, Roberto Latagliata, Sergio Amadori, Franco Mandelli

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Because of the lack of standard treatment in refractory and relapsed acute myelogenous leukemia (AML) several new drugs have been employed alone to evaluate their efficacy in this peculiar category of patient. Bisantrene, a new anthracene bishydrazone derivative, has shown antileukemic effect in phase I and II clinical trials with acceptable extrahaematological toxicity. Seven patients (six males and one female, median age 41.8 years) received Bisantrene (250 mg/sqm/daily 1-7) as a single agent in relapsed or refractory leukemia. 5 out of 7 patients achieved complete remission, one attained partial remission and one was resistant. However, haematological toxicity was severe with prolonged myelosuppression. Hepatic toxicity was the main extrahaematological side effect and occurred in 3 of 7 patients, however all of them recovered within 40 days. No cardiovascular dysfunction occurred although all the patients had been heavily previously treated with anthracyclines. Our data confirm that Bisantrere is active in relapsed and refractory AML and suggest the need for larger clinical trials to better evaluate its efficacy.

Original languageEnglish
Pages (from-to)217-220
Number of pages4
JournalLeukemia and Lymphoma
Volume9
Issue number3
DOIs
Publication statusPublished - 1993

Fingerprint

bisantrene
Acute Myeloid Leukemia
Phase II Clinical Trials
Clinical Trials, Phase I
Anthracyclines
Leukemia
Clinical Trials
Liver

Keywords

  • Bisantrene
  • Chemotherapy
  • Relapsed/refractory acute myelogenous leukemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Spadea, A., Petti, M. C., Aloespiriti, M. A., Avvisati, G., Gregoris, C. D., Fazi, P., ... Mandelli, F. (1993). Bisantrene in relapsed and refractory acute myelogenous leukemia. Leukemia and Lymphoma, 9(3), 217-220. https://doi.org/10.3109/10428199309147373

Bisantrene in relapsed and refractory acute myelogenous leukemia. / Spadea, Antonio; Petti, Maria Concetta; Aloespiriti, Maria Antonietta; Avvisati, Giuseppe; Gregoris, Cinzia De; Fazi, Paola; Latagliata, Roberto; Amadori, Sergio; Mandelli, Franco.

In: Leukemia and Lymphoma, Vol. 9, No. 3, 1993, p. 217-220.

Research output: Contribution to journalArticle

Spadea, A, Petti, MC, Aloespiriti, MA, Avvisati, G, Gregoris, CD, Fazi, P, Latagliata, R, Amadori, S & Mandelli, F 1993, 'Bisantrene in relapsed and refractory acute myelogenous leukemia', Leukemia and Lymphoma, vol. 9, no. 3, pp. 217-220. https://doi.org/10.3109/10428199309147373
Spadea A, Petti MC, Aloespiriti MA, Avvisati G, Gregoris CD, Fazi P et al. Bisantrene in relapsed and refractory acute myelogenous leukemia. Leukemia and Lymphoma. 1993;9(3):217-220. https://doi.org/10.3109/10428199309147373
Spadea, Antonio ; Petti, Maria Concetta ; Aloespiriti, Maria Antonietta ; Avvisati, Giuseppe ; Gregoris, Cinzia De ; Fazi, Paola ; Latagliata, Roberto ; Amadori, Sergio ; Mandelli, Franco. / Bisantrene in relapsed and refractory acute myelogenous leukemia. In: Leukemia and Lymphoma. 1993 ; Vol. 9, No. 3. pp. 217-220.
@article{badc7b205d994b9e92c30ca72521243f,
title = "Bisantrene in relapsed and refractory acute myelogenous leukemia",
abstract = "Because of the lack of standard treatment in refractory and relapsed acute myelogenous leukemia (AML) several new drugs have been employed alone to evaluate their efficacy in this peculiar category of patient. Bisantrene, a new anthracene bishydrazone derivative, has shown antileukemic effect in phase I and II clinical trials with acceptable extrahaematological toxicity. Seven patients (six males and one female, median age 41.8 years) received Bisantrene (250 mg/sqm/daily 1-7) as a single agent in relapsed or refractory leukemia. 5 out of 7 patients achieved complete remission, one attained partial remission and one was resistant. However, haematological toxicity was severe with prolonged myelosuppression. Hepatic toxicity was the main extrahaematological side effect and occurred in 3 of 7 patients, however all of them recovered within 40 days. No cardiovascular dysfunction occurred although all the patients had been heavily previously treated with anthracyclines. Our data confirm that Bisantrere is active in relapsed and refractory AML and suggest the need for larger clinical trials to better evaluate its efficacy.",
keywords = "Bisantrene, Chemotherapy, Relapsed/refractory acute myelogenous leukemia",
author = "Antonio Spadea and Petti, {Maria Concetta} and Aloespiriti, {Maria Antonietta} and Giuseppe Avvisati and Gregoris, {Cinzia De} and Paola Fazi and Roberto Latagliata and Sergio Amadori and Franco Mandelli",
year = "1993",
doi = "10.3109/10428199309147373",
language = "English",
volume = "9",
pages = "217--220",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Bisantrene in relapsed and refractory acute myelogenous leukemia

AU - Spadea, Antonio

AU - Petti, Maria Concetta

AU - Aloespiriti, Maria Antonietta

AU - Avvisati, Giuseppe

AU - Gregoris, Cinzia De

AU - Fazi, Paola

AU - Latagliata, Roberto

AU - Amadori, Sergio

AU - Mandelli, Franco

PY - 1993

Y1 - 1993

N2 - Because of the lack of standard treatment in refractory and relapsed acute myelogenous leukemia (AML) several new drugs have been employed alone to evaluate their efficacy in this peculiar category of patient. Bisantrene, a new anthracene bishydrazone derivative, has shown antileukemic effect in phase I and II clinical trials with acceptable extrahaematological toxicity. Seven patients (six males and one female, median age 41.8 years) received Bisantrene (250 mg/sqm/daily 1-7) as a single agent in relapsed or refractory leukemia. 5 out of 7 patients achieved complete remission, one attained partial remission and one was resistant. However, haematological toxicity was severe with prolonged myelosuppression. Hepatic toxicity was the main extrahaematological side effect and occurred in 3 of 7 patients, however all of them recovered within 40 days. No cardiovascular dysfunction occurred although all the patients had been heavily previously treated with anthracyclines. Our data confirm that Bisantrere is active in relapsed and refractory AML and suggest the need for larger clinical trials to better evaluate its efficacy.

AB - Because of the lack of standard treatment in refractory and relapsed acute myelogenous leukemia (AML) several new drugs have been employed alone to evaluate their efficacy in this peculiar category of patient. Bisantrene, a new anthracene bishydrazone derivative, has shown antileukemic effect in phase I and II clinical trials with acceptable extrahaematological toxicity. Seven patients (six males and one female, median age 41.8 years) received Bisantrene (250 mg/sqm/daily 1-7) as a single agent in relapsed or refractory leukemia. 5 out of 7 patients achieved complete remission, one attained partial remission and one was resistant. However, haematological toxicity was severe with prolonged myelosuppression. Hepatic toxicity was the main extrahaematological side effect and occurred in 3 of 7 patients, however all of them recovered within 40 days. No cardiovascular dysfunction occurred although all the patients had been heavily previously treated with anthracyclines. Our data confirm that Bisantrere is active in relapsed and refractory AML and suggest the need for larger clinical trials to better evaluate its efficacy.

KW - Bisantrene

KW - Chemotherapy

KW - Relapsed/refractory acute myelogenous leukemia

UR - http://www.scopus.com/inward/record.url?scp=0027172853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027172853&partnerID=8YFLogxK

U2 - 10.3109/10428199309147373

DO - 10.3109/10428199309147373

M3 - Article

VL - 9

SP - 217

EP - 220

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3

ER -